CMTx Biotech, Inc. Information

CMTx Biotech is commercializing a pipeline of proprietary, non-antibiotic, chemically-modified tetracycline (CMT) compositions and formulations for the host-modulatory treatment of diseases with high unmet needs. The company’s lead drug candidate is a clinical-stage, orally-administered small molecule (incyclinide / CMT-3 / COL-3) for the treatment of hospitalized sepsis patients at risk of septic shock, multiple organ dysfunction syndrome (MODS) and acute respiratory distress syndrome (ARDS), including from SARS-CoV-2 infection (COVID-19) and other infectious diseases. Our clinical-stage drug candidate has already demonstrated impressive efficacy in a number of animal models of sepsis/ARDS/MODS across multiple species (rats, mice, pigs, sheep). It has also been evaluated in over 450 patients across eleven Phase I/II clinical studies, which showed that the drug is well-tolerated. CMTx Biotech also has a pipeline of pre-clinical stage analogues for the treatment of diseases with high unmet need.